Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.59 |
| ▸ | GRM5 | P41594 | 11/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591544 | 1.00 | GRM1 (0.59) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL24289433 | 0.86 | GRM1 (0.51) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL6621771 | 0.85 | PDE10A (0.60) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL2212585 | 0.83 | NAMPT (0.53) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL16272023 | 0.82 | GRM1 (0.59) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL30308912 | 0.82 | GRM1 (0.64) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL4251822 | 0.81 | GRM5 (0.70) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL29559340 | 0.81 | GRM5 (0.70) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL23015101 | 0.81 | GRM1 (0.57) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL20810424 | 0.80 | WNT3A (0.45) | GRM1GRM5PDK4PDE10ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| EP-1087962-A4 | PREPARATION OF HETEROARYL COMPOUNDS | LILLY CO ELI (US) | 2001-10-04 | — | — | EP | disclosed |
| CN-1315830-A | Method for treating anxiety disorders | LILLY CO ELI (US) | 2001-10-03 | — | — | CN | disclosed |
| US-6242450-B1 | SUBSTITUTED PIPERIDINES | ELI LILLY AND COMPANY | 2001-06-05 | — | — | US | disclosed |
| EP-1087962-A1 | PREPARATION OF HETEROARYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000006082-A2 | TREATMENT OF ANXIETY DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006166-A1 | 5-HT1F ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976746-A1 | 5-HT1F antagonists | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0976747-A2 | Use of 5HT-1F receptor antagonists for treating anxiety disorders | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999065896-A1 | PREPARATION OF HETEROARYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | GRM1 744/4885GRM5 2249/4885PDK4 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.